Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition? Tamer OthmanAlex HerreraMatthew Mei T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) 06 January 2021 Pages: 1 - 7
High-Risk Mantle Cell Lymphoma in the Era of Novel Agents Edward NabrinskyAlexey V. DanilovPaul B. Koller T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) 28 January 2021 Pages: 8 - 18
A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine Narendranath EpperlaMehdi Hamadani T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) 25 January 2021 Pages: 19 - 24
Targeted Therapies for Follicular Lymphoma Jennifer GirardYasmin KarimiTycel Phillips T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) 22 March 2021 Pages: 25 - 31
Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies Taha Al-JuhaishiSairah Ahmed T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) 25 February 2021 Pages: 32 - 39
Lessons Learned Treating Patients with Multiple Myeloma in Resource-Constrained Settings Guillermo J. Ruiz-ArgüellesDavid Gómez-Almaguer Multiple Myeloma (P Kapoor, Section Editor) 11 March 2021 Pages: 40 - 44
When to Use Targeted Therapy for the Treatment of Follicular Lymphoma Loretta J. Nastoupil B Cell NHL, T Cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 02 April 2021 Pages: 45 - 51
Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra Francesca MontanariManuela Orjuela-Grimm B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 05 February 2021 Pages: 52 - 60
AYA Considerations for Aggressive Lymphomas Gabriela LlauradorLisa Giulino-Roth B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 16 March 2021 Pages: 61 - 71
Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma Anupama DoraiswamyMansi R. ShahRajat Bannerji B Cell NHL, T Cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 22 February 2021 Pages: 72 - 81
Invited Review: Will Consolidation with ASCT Be a Thing of the Past for MCL and PTCL? Alessandro BroccoliLisa ArgnaniPier Luigi Zinzani Topical Collection on B Cell NHL, T Cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 01 March 2021 Pages: 82 - 88
An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia Sangeetha VenugopalNaval DaverFarhad Ravandi Acute Myeloid Leukemias (U Borate, Section Editor) 25 February 2021 Pages: 89 - 96
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options Daniel R. RichardsonSteven D. GreenJoshua F. Zeidner Acute Myeloid Leukemias (U Borate, Section Editor) 20 February 2021 Pages: 97 - 111
High-Dimensional Immune Monitoring for Chimeric Antigen Receptor T Cell Therapies Sujata SharmaDavid QuinnIulian Pruteanu-Malinici CART and Immunotherapy (M Ruella and P Hanley, Section Editors) 15 January 2021 Pages: 112 - 116